You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Polatuzumab

Showing 51 - 56 of 56
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Non-Hodgkin Lymphoma Trial in Worldwide (Epcoritamab, Lenalidomide, Ibrutinib)

Recruiting
  • Non-Hodgkin Lymphoma
  • Tucson, Arizona
  • +81 more
Jan 25, 2023

Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in Valhalla (DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B)

Recruiting
  • Non-hodgkin Lymphoma
  • Hodgkin Lymphoma
  • DOC Group B
  • +16 more
  • Valhalla, New York
    New York Medical College
Jun 9, 2022

Follicular Lymphoma, DLBCL Trial in Worldwide (Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin)

Completed
Has Results
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Los Angeles, California
  • +40 more
Feb 20, 2020

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia Trial in Worldwide (Polatuzumab Vedotin, Rituximab)

    Completed
    • Non-Hodgkins Lymphoma
    • Chronic Lymphocytic Leukemia
    • Stanford, California
    • +15 more
    Jun 14, 2017